Triomics

Triomics is helping cancer care providers by reducing the burden associated with manually reviewing patient charts. Utilizing our OncoLLM™:a family of oncology-focused language models:we are able to accelerate clinical trial enrollment, power quality improvement projects, and address many other key strategic priorities.

High-Level Overview

Triomics is a software company that leverages Generative AI specifically tailored for oncology electronic health records (EHRs) to reduce the manual workload in cancer research and care[1][3]. Its core product, OncoLLM, is an enterprise-grade AI platform designed to interpret complex oncology data at the patient level, automating data abstraction and enabling real-world decision-making at scale[2]. Triomics primarily serves cancer centers, healthcare institutions, and life sciences organizations, helping them accelerate clinical trial enrollment, improve quality projects, and streamline healthcare operations by transforming unstructured oncology data into actionable insights[3].

For an investment firm, Triomics represents a cutting-edge AI healthcare startup focused on oncology, with a mission to improve cancer patient outcomes and healthcare team efficiency through responsible AI innovation[5]. Its investment appeal lies in its specialization in oncology, strong partnerships with top cancer centers, and demonstrated impact such as a documented >30% increase in trial accruals and 95% accuracy in data extraction[3]. Triomics contributes to the startup ecosystem by advancing AI applications in healthcare, particularly in a high-impact, data-intensive domain like oncology.

Origin Story

Triomics was founded in 2021 in San Francisco by a multidisciplinary team: Sarim Khan (chemical engineer with research experience), Sajjan Rajpurohit (medical oncologist with 12+ years of experience), and Hrituraj Singh (former Adobe Research scientist specializing in language models)[4]. The idea emerged from recognizing the lack of vertical integration in clinical trial processes and the heavy manual burden of reviewing oncology patient charts. Early traction included partnerships with leading institutions such as Memorial Sloan Kettering Cancer Center and a $15M Series A funding round in 2024, validating the market need and technology efficacy[4][6][7].

Core Differentiators

• Oncology-Specific AI Framework: OncoLLM is not a single model but a modular system of 8 interoperable AI models (3B to 72B parameters) designed to interpret patient-level data rather than just document-level keywords, enabling nuanced understanding akin to oncology specialists[2].
• High Accuracy and Customization: The platform achieves over 95% accuracy on custom data dictionaries tailored to client needs, supporting complex curation tasks like cancer registries and evidence generation[3].
• Workflow Integration: Triomics delivers insights directly into clinical workflows, automating trial matching and data abstraction to free clinicians from manual chart reviews[3][4].
• Strong Consortium Leadership: Triomics leads the Collaboration for Oncology focused LLM Training (COLT), a consortium of 20+ NCI-designated cancer centers, setting benchmarks and safety standards for AI in oncology[5].
• Scalable and Production-Ready: Designed for enterprise deployment with continuous support and monitoring, ensuring reliability in critical oncology environments[2][5].

Role in the Broader Tech Landscape

Triomics rides the wave of generative AI adoption in healthcare, specifically targeting the oncology domain where data complexity and manual workload have historically limited research and care efficiency. The timing is critical as oncology generates vast amounts of unstructured data (notes, PDFs, scanned faxes) that traditional systems cannot efficiently process. Market forces such as increasing clinical trial complexity, demand for personalized medicine, and healthcare digitization favor AI-driven solutions like Triomics. By enabling faster trial enrollment and better data utilization, Triomics influences the broader ecosystem by accelerating oncology research and improving patient care workflows, setting a precedent for specialized AI applications in healthcare[1][3][5].

Quick Take & Future Outlook

Triomics is poised for significant growth as it expands partnerships with leading cancer centers and life sciences organizations, further refining its AI models and scaling deployment. Future trends shaping its journey include advances in large language models, increasing regulatory clarity around AI in healthcare, and growing demand for real-world evidence generation. Triomics’ influence may evolve from a niche oncology AI provider to a foundational platform underpinning multiple facets of cancer care and research, potentially expanding into adjacent therapeutic areas. Its commitment to responsible innovation and consortium leadership positions it well to navigate the zero-fail stakes of oncology[5].

In summary, Triomics exemplifies how specialized generative AI can transform oncology EHR data into actionable insights, reducing manual burdens and accelerating cancer research and care, making it a compelling player at the intersection of AI and healthcare.